CN101119750B - 抗癌治疗 - Google Patents

抗癌治疗 Download PDF

Info

Publication number
CN101119750B
CN101119750B CN2005800369316A CN200580036931A CN101119750B CN 101119750 B CN101119750 B CN 101119750B CN 2005800369316 A CN2005800369316 A CN 2005800369316A CN 200580036931 A CN200580036931 A CN 200580036931A CN 101119750 B CN101119750 B CN 101119750B
Authority
CN
China
Prior art keywords
dose
pld
cancer
administered
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800369316A
Other languages
English (en)
Chinese (zh)
Other versions
CN101119750A (zh
Inventor
E·吉勒斯
L·-A·斯特纳斯
O·特里凡
H·范德韦尔德
A·泰特尔鲍姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yangsen Products Co ltd
Pharmamar SA
Janssen Products LP
Original Assignee
Pharmamar SA
Ortho Biotech Products LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36096124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101119750(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmamar SA, Ortho Biotech Products LP filed Critical Pharmamar SA
Publication of CN101119750A publication Critical patent/CN101119750A/zh
Application granted granted Critical
Publication of CN101119750B publication Critical patent/CN101119750B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2005800369316A 2004-10-26 2005-10-26 抗癌治疗 Expired - Lifetime CN101119750B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62216304P 2004-10-26 2004-10-26
US60/622,163 2004-10-26
PCT/GB2005/050189 WO2006046080A2 (en) 2004-10-26 2005-10-26 Pegylated liposomal doxorubicin in combination with ecteinescidin 743

Publications (2)

Publication Number Publication Date
CN101119750A CN101119750A (zh) 2008-02-06
CN101119750B true CN101119750B (zh) 2013-03-06

Family

ID=36096124

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800369316A Expired - Lifetime CN101119750B (zh) 2004-10-26 2005-10-26 抗癌治疗

Country Status (26)

Country Link
US (1) US20090117176A1 (https=)
EP (1) EP1827500B1 (https=)
JP (2) JP4554684B2 (https=)
KR (1) KR101287918B1 (https=)
CN (1) CN101119750B (https=)
AT (1) ATE430586T1 (https=)
AU (1) AU2005298364B2 (https=)
BR (1) BRPI0518250A2 (https=)
CA (1) CA2582452C (https=)
CY (1) CY1110329T1 (https=)
DE (1) DE602005014380D1 (https=)
DK (1) DK1827500T3 (https=)
ES (1) ES2326825T3 (https=)
HR (1) HRP20090345T1 (https=)
IL (1) IL182352A (https=)
MX (1) MX2007004744A (https=)
NO (1) NO328958B1 (https=)
NZ (1) NZ554765A (https=)
PL (1) PL1827500T3 (https=)
PT (1) PT1827500E (https=)
RS (1) RS50822B (https=)
RU (1) RU2359700C2 (https=)
SI (1) SI1827500T1 (https=)
UA (1) UA87877C2 (https=)
WO (1) WO2006046080A2 (https=)
ZA (1) ZA200703396B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1365808B1 (en) * 2000-11-06 2011-01-19 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
DE602004016376D1 (de) 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CN101489593B (zh) 2006-06-19 2015-11-25 约翰·霍普金斯大学 通过脂质体酶的治疗剂肿瘤特异性递送
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
RU2758669C2 (ru) * 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
RU2657835C1 (ru) * 2017-11-28 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ получения системы для доставки противоопухолевого препарата в клетки опухоли

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1360503A (zh) * 1999-05-13 2002-07-24 法马马有限公司 用于治疗癌症的海鞘素743的组合物和用途
CN1486193A (zh) * 2000-11-06 2004-03-31 有效的抗肿瘤治疗方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CN1157189C (zh) * 1998-04-06 2004-07-14 伊利诺伊大学评议会 半合成海鞘素
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
US20020137663A1 (en) * 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
ES2256305T3 (es) * 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
EE200300429A (et) * 2001-03-06 2003-12-15 Bristol-Myers Squibb Company Tegafuri, uratsiili, foliinhappe, paklitakseeli ja karboplatiini kasutamine ravimkoostise valmistamiseks kasvaja raviks
CA2449856C (en) * 2001-06-15 2009-03-10 Cornerstone Pharmaceuticals Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
BR0213424A (pt) * 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
WO2004006755A2 (en) * 2002-07-16 2004-01-22 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Support bra for ultrasonic breast scanner
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DE602004016376D1 (de) * 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
MX2007000360A (es) * 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
RS50510B (sr) * 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
DE602006020335D1 (de) * 2005-11-25 2011-04-07 Pharma Mar Sa Verwendung von parp-1-hemmern
US20080075772A1 (en) * 2006-04-13 2008-03-27 Lawrence Solomon Pharmaceutical compositions having novel scoring patterns and methods of using those compositions
JP2009536956A (ja) * 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1360503A (zh) * 1999-05-13 2002-07-24 法马马有限公司 用于治疗癌症的海鞘素743的组合物和用途
CN1486193A (zh) * 2000-11-06 2004-03-31 有效的抗肿瘤治疗方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
文旭等.脂质体多柔比星药物动力学研究进展.中国新药与临床杂志vol.20 no.3.2001,20(3),第216-219页.
文旭等.脂质体多柔比星药物动力学研究进展.中国新药与临床杂志vol.20 no.3.2001,20(3),第216-219页. *

Also Published As

Publication number Publication date
PL1827500T3 (pl) 2009-09-30
NO20072543L (no) 2007-07-13
JP2009292850A (ja) 2009-12-17
AU2005298364A1 (en) 2006-05-04
ZA200703396B (en) 2008-11-26
MX2007004744A (es) 2007-10-23
US20090117176A1 (en) 2009-05-07
EP1827500B1 (en) 2009-05-06
RS50822B (sr) 2010-08-31
PT1827500E (pt) 2009-08-05
NZ554765A (en) 2010-01-29
WO2006046080A8 (en) 2007-07-12
KR101287918B1 (ko) 2013-07-19
JP4554684B2 (ja) 2010-09-29
ES2326825T3 (es) 2009-10-20
DE602005014380D1 (de) 2009-06-18
EP1827500A2 (en) 2007-09-05
CA2582452A1 (en) 2006-05-04
HK1107766A1 (en) 2008-04-18
BRPI0518250A2 (pt) 2008-11-11
CY1110329T1 (el) 2015-01-14
WO2006046080A3 (en) 2006-10-19
UA87877C2 (en) 2009-08-25
ATE430586T1 (de) 2009-05-15
NO328958B1 (no) 2010-06-28
WO2006046080A2 (en) 2006-05-04
CN101119750A (zh) 2008-02-06
JP2008517991A (ja) 2008-05-29
IL182352A0 (en) 2007-07-24
KR20070108135A (ko) 2007-11-08
AU2005298364B2 (en) 2009-03-26
SI1827500T1 (sl) 2009-10-31
RU2359700C2 (ru) 2009-06-27
HRP20090345T1 (en) 2009-08-31
DK1827500T3 (da) 2009-08-31
RU2007119545A (ru) 2008-12-10
CA2582452C (en) 2010-09-07
IL182352A (en) 2016-07-31

Similar Documents

Publication Publication Date Title
JP2009292850A (ja) 抗癌治療
CN100374162C (zh) 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
KR20160023816A (ko) 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
EP1323423B1 (en) Combined preparation comprising a morpholinyl anthracycline derivative and a topoisomerase II inhibitor
JP2017516784A (ja) がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用
CA2550505A1 (en) Copper antagonist compounds
JP2002507571A (ja) アントラサイクリン誘導体とカンプトテシン誘導体の相乗組合せを含有する抗腫瘍組成物
CN101123966A (zh) 包含使用et-743和多柔比星来治疗癌症的联合疗法
US10617672B2 (en) Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C
JP2014088398A (ja) 肝臓腫瘍治療へのアントラサイクリン誘導体の使用
EP3151864A1 (en) Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
Harrington et al. Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours
PT1781255E (pt) Composições e métodos para tratamento da leucemia
CN102781238A (zh) Tivozanib和坦罗莫司的组合
JP2022517352A (ja) マイトマイシンｃのリポソーム化プロドラッグを含むリポソーム組成物および製造法
HK1107766B (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
JP2019131508A (ja) ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
JP2009501707A (ja) 癌の処置のためのゾスキダル、ダウノルビシン、およびシタラビン
ZA200508696B (en) Use of irinotecan for treatment of resistant breast cancer
US20200390702A1 (en) Liposomal taxanes for treatment of sclc
JP2003261448A (ja) 抗腫瘍剤
HK40044845A (en) Use of mitoxantrone liposome for treating non-hodgkin’s lymphoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: Madrid

Patentee after: PHARMA MAR, S.A.

Patentee after: Yangsen Products Co.,Ltd.

Address before: Madrid

Patentee before: PHARMA MAR, S.A.

Patentee before: Centocor Ortho Biotech Product

Address after: Madrid

Patentee after: PHARMA MAR, S.A.

Patentee after: CENTOCOR ORTHO BIOTECH PRODUCT

Address before: Madrid

Patentee before: PHARMA MAR, S.A.

Patentee before: Aosuo Biotechnology Product Partners Co.,Ltd.

CX01 Expiry of patent term

Granted publication date: 20130306

CX01 Expiry of patent term